ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)

Contract Value

Not provided

Codes & Classification
Solicitation Number

ARPA-H-SOL-26-165

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN13

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
The Advanced Research Projects Agency for Health (ARPA-H) has released a solicitation titled "Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening" under procurement identifier ARPA-H-SOL-26-165. This initiative represents a significant research and development opportunity aimed at advancing the understanding of tissue aging in microgravity environments, with the ultimate goal of transforming drug discovery and development processes. Purpose and Scope: The COSMOS initiative seeks to rigorously determine whether exposure to microgravity in Low Earth Orbit (LEO) accelerates tissue aging across multiple organ systems—specifically brain, cardiac, uterine, and kidney tissues—spanning several adult age brackets. The central hypothesis is that if the Tissue Aging Rate in Space (TARIS) is demonstrably higher than the Tissue Aging Rate on Earth (TAROE), and this acceleration surpasses the cost-effectiveness threshold for new drug research and development (R&D) on Earth, then LEO could serve as a revolutionary platform for drug screening. The intended outcome is to establish a fully autonomous, high-throughput drug screening platform in space, offering a faster and more cost-effective alternative to traditional Earth-based drug R&D. Key Requirements and Objectives: Offerors are expected to propose innovative experimental designs that can definitively measure and compare tissue aging rates in space versus Earth. The solicitation emphasizes the need for robust, autonomous systems capable of operating in the unique environment of LEO, with a focus on high-throughput capabilities. The research must address multiple tissue types and age groups, ensuring comprehensive data collection and analysis. Amendments to the solicitation have clarified and updated requirements related to experimental design and technical details, underscoring the importance of methodological rigor and clarity in proposed solutions. Expected Deliverables: Successful proposals will deliver validated experimental platforms and protocols for tissue aging studies in microgravity, along with comprehensive data sets comparing TARIS and TAROE. Should the hypothesis be confirmed, the deliverables will also include a scalable framework for autonomous drug screening in LEO, potentially setting a new standard for pharmaceutical R&D. Contracting Entity and Contact Information: This opportunity is managed by the Advanced Research Projects Agency for Health (ARPA-H), a federal office within the Department of Health and Human Services, under the National Institutes of Health. The primary point of contact for this solicitation is the COSMOS Team, reachable at [email protected]. Location and Classification: The procurement is classified under NAICS code 541714, "Research and Development in Biotechnology (except Nanobiotechnology)," with the 2022 version year. The Product Service Code is AN13, further indicating a focus on advanced biotechnology research. Procurement Type and Special Considerations: ARPA-H anticipates making multiple awards under Other Transaction Authority (OTA), which allows for flexible, non-traditional contracting mechanisms suited to innovative research and development activities. The solicitation has undergone several amendments, including updates to submission deadlines, experimental design requirements, and technical clarifications. Interested parties are encouraged to review all attachments and amendments available on the official SAM.gov opportunity page. Set-Aside Requirements: No specific set-aside requirements or preferences have been indicated in the provided information. Summary: The COSMOS Innovative Solutions Opening represents a unique and ambitious opportunity for organizations specializing in biotechnology research, space-based experimentation, and autonomous systems development. Contractors with expertise in tissue modeling, microgravity research, and high-throughput screening technologies are particularly well-suited to contribute to this groundbreaking initiative. The project’s outcomes have the potential to redefine the landscape of drug discovery, leveraging the unique environment of space to accelerate biomedical innovation. For further details, including solicitation documents and amendments, interested parties should consult the official notice at https://sam.gov/opp/d38a0249fdb64fbabceb7eef112d6f07/view and direct any inquiries to the COSMOS Team at [email protected].
Documents10